Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Vaccines

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 372 articles:
HTML format



Single Articles


    June 2022
  1. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: How Effective is Covid-19 Vaccination in Children?
    N Engl J Med. 2022;386:e78.
    PubMed    


  2. LARSON HJ, Gakidou E, Murray CJL
    The Vaccine-Hesitant Moment.
    N Engl J Med. 2022 Jun 29. doi: 10.1056/NEJMra2106441.
    PubMed    


  3. WAXMAN JG, Magen O, Hernan MA
    Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine. Reply.
    N Engl J Med. 2022;387.
    PubMed    


  4. TUMMINIA A, Romano M
    Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine.
    N Engl J Med. 2022;387.
    PubMed    


  5. COHEN-STAVI CJ, Magen O, Barda N, Yaron S, et al
    BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age.
    N Engl J Med. 2022 Jun 29. doi: 10.1056/NEJMoa2205011.
    PubMed     Abstract available


  6. LAUNAY O, Cachanado M, Luong Nguyen LB, Ninove L, et al
    Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine.
    N Engl J Med. 2022 Jun 29. doi: 10.1056/NEJMc2206711.
    PubMed    


  7. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Vaccinating Young Children against Covid-19.
    N Engl J Med. 2022;386:e77.
    PubMed    


  8. SCHMOELE-THOMA B, Zareba AM, Jiang Q, Maddur MS, et al
    Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study.
    N Engl J Med. 2022;386:2377-2386.
    PubMed     Abstract available


  9. BAR-ON YM, Goldberg Y, Milo R
    Protection by a Fourth Dose of BNT162b2 against Omicron in Israel. Reply.
    N Engl J Med. 2022;386:2441-2442.
    PubMed    


  10. WOHL A, Leibowitz R
    Protection by a Fourth Dose of BNT162b2 against Omicron in Israel.
    N Engl J Med. 2022;386:2441.
    PubMed    


  11. DESILVA M, Haapala J, Vazquez-Benitez G, Vesco KK, et al
    Evaluation of Acute Adverse Events after Covid-19 Vaccination during Pregnancy.
    N Engl J Med. 2022 Jun 22. doi: 10.1056/NEJMc2205276.
    PubMed    


  12. HALASA NB, Olson SM, Staat MA, Newhams MM, et al
    Maternal Vaccination and Risk of Hospitalization for Covid-19 among Infants.
    N Engl J Med. 2022 Jun 22. doi: 10.1056/NEJMoa2204399.
    PubMed     Abstract available


  13. RASMUSSEN SA, Jamieson DJ
    Covid-19 Vaccination during Pregnancy - Two for the Price of One.
    N Engl J Med. 2022 Jun 22. doi: 10.1056/NEJMe2206730.
    PubMed    


  14. PRICE AM, Olson SM, Patel MM
    BNT162b2 Protection against the Omicron Variant in Children and Adolescents. Reply.
    N Engl J Med. 2022;386:2346.
    PubMed    


  15. ZENG G
    BNT162b2 Protection against the Omicron Variant in Children and Adolescents.
    N Engl J Med. 2022;386:2345-2346.
    PubMed    


  16. LEUCHTER RK, Jackson NJ, Mafi JN, Sarkisian CA, et al
    Association between Covid-19 Vaccination and Influenza Vaccination Rates.
    N Engl J Med. 2022 Jun 15. doi: 10.1056/NEJMc2204560.
    PubMed    


  17. HOPKINS S, Hall V, Klenerman P
    Protection against SARS-CoV-2 after Vaccination and Previous Infection. Reply.
    N Engl J Med. 2022;386.
    PubMed    


  18. MATUCHANSKY C
    Protection against SARS-CoV-2 after Vaccination and Previous Infection.
    N Engl J Med. 2022;386.
    PubMed    


  19. ALTARAWNEH HN, Chemaitelly H, Ayoub HH, Tang P, et al
    Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections.
    N Engl J Med. 2022 Jun 15. doi: 10.1056/NEJMoa2203965.
    PubMed     Abstract available


    May 2022
  20. GOLDBERG Y, Mandel M, Bar-On YM, Bodenheimer O, et al
    Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2.
    N Engl J Med. 2022 May 25. doi: 10.1056/NEJMoa2118946.
    PubMed     Abstract available


  21. ACCORSI EK, Britton A, Shang N, Fleming-Dutra KE, et al
    Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron.
    N Engl J Med. 2022 May 25. doi: 10.1056/NEJMc2203165.
    PubMed    


  22. BROWN PE, Fu SH, Bansal A, Newcombe L, et al
    Omicron BA.1/1.1 SARS-CoV-2 Infection among Vaccinated Canadian Adults.
    N Engl J Med. 2022 May 18. doi: 10.1056/NEJMc2202879.
    PubMed    


  23. CREECH CB, Anderson E, Berthaud V, Yildirim I, et al
    Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age.
    N Engl J Med. 2022 May 11. doi: 10.1056/NEJMoa2203315.
    PubMed     Abstract available


  24. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Do We Need New Covid-19 Vaccines?
    N Engl J Med. 2022;386:e52.
    PubMed    


  25. HAGER KJ, Perez Marc G, Gobeil P, Diaz RS, et al
    Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine.
    N Engl J Med. 2022 May 4. doi: 10.1056/NEJMoa2201300.
    PubMed     Abstract available


  26. GRAY G, Collie S, Goga A, Garrett N, et al
    Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa.
    N Engl J Med. 2022 May 4. doi: 10.1056/NEJMc2202061.
    PubMed    


  27. DAI L, Gao L, Tao L, Hadinegoro SR, et al
    Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults.
    N Engl J Med. 2022 May 4. doi: 10.1056/NEJMoa2202261.
    PubMed     Abstract available


  28. NOHYNEK H, Wilder-Smith A
    Does the World Still Need New Covid-19 Vaccines?
    N Engl J Med. 2022 May 4. doi: 10.1056/NEJMe2204695.
    PubMed    


    April 2022
  29. MEISSNER HC
    Understanding Vaccine Safety and the Roles of the FDA and the CDC.
    N Engl J Med. 2022;386:1638-1645.
    PubMed    


  30. SIMOES EAF, Center KJ, Tita ATN, Swanson KA, et al
    Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in Pregnancy.
    N Engl J Med. 2022;386:1615-1626.
    PubMed     Abstract available


  31. RUBIN EJ, Baden LR, Bloom BR, Morrissey S, et al
    Audio Interview: Do the Tobacco Wars Offer Any Lessons for the Vaccine Wars?
    N Engl J Med. 2022;386:e48.
    PubMed    


  32. BAZELL R, Koh H, Bloom BR
    The Tobacco Wars' Lessons for the Vaccination Wars.
    N Engl J Med. 2022 Apr 13. doi: 10.1056/NEJMp2202618.
    PubMed    


  33. MAGEN O, Waxman JG, Makov-Assif M, Vered R, et al
    Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.
    N Engl J Med. 2022 Apr 13. doi: 10.1056/NEJMoa2201688.
    PubMed     Abstract available


  34. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Do We Need a Fourth Dose of Covid Vaccine?
    N Engl J Med. 2022;386:e45.
    PubMed    


  35. YOON SK, Hegmann KT, Thiese MS, Burgess JL, et al
    Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers.
    N Engl J Med. 2022 Apr 6. doi: 10.1056/NEJMc2201821.
    PubMed    


  36. BAR-ON YM, Goldberg Y, Mandel M, Bodenheimer O, et al
    Protection by a Fourth Dose of BNT162b2 against Omicron in Israel.
    N Engl J Med. 2022 Apr 5. doi: 10.1056/NEJMoa2201570.
    PubMed     Abstract available


    March 2022
  37. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Effectiveness of Covid-19 Vaccination in Children.
    N Engl J Med. 2022;386:e39.
    PubMed    


  38. KLEIN NP
    Added Benefit of Covid-19 Vaccination after Previous Infection.
    N Engl J Med. 2022;386:1278-1279.
    PubMed    


  39. PRICE AM, Olson SM, Newhams MM, Halasa NB, et al
    BNT162b2 Protection against the Omicron Variant in Children and Adolescents.
    N Engl J Med. 2022 Mar 30. doi: 10.1056/NEJMoa2202826.
    PubMed     Abstract available


  40. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Covid-19: Why We Publish What We Do.
    N Engl J Med. 2022;386:e38.
    PubMed    


  41. MOREIRA ED JR, Kitchin N, Xu X, Dychter SS, et al
    Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine.
    N Engl J Med. 2022 Mar 23. doi: 10.1056/NEJMoa2200674.
    PubMed     Abstract available


  42. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Can We Make More Effective Covid-19 Vaccines?
    N Engl J Med. 2022;386:e36.
    PubMed    


  43. REGEV-YOCHAY G, Gonen T, Gilboa M, Mandelboim M, et al
    Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron.
    N Engl J Med. 2022 Mar 16. doi: 10.1056/NEJMc2202542.
    PubMed    


  44. ALONSO PL, O'Brien KL
    A Malaria Vaccine for Africa - An Important Step in a Century-Long Quest.
    N Engl J Med. 2022 Mar 12. doi: 10.1056/NEJMp2116591.
    PubMed    


  45. RUBIN EJ, Baden LR, Hunter D, Morrissey S, et al
    Audio Interview: Making Covid-19 Vaccines Available around the World.
    N Engl J Med. 2022;386:e31.
    PubMed    


  46. ABU-RADDAD LJ, Chemaitelly H, Ayoub HH, AlMukdad S, et al
    Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.
    N Engl J Med. 2022 Mar 9. doi: 10.1056/NEJMoa2200797.
    PubMed     Abstract available


  47. MONTO AS
    The Future of SARS-CoV-2 Vaccination. Reply.
    N Engl J Med. 2022;386:899-900.
    PubMed    


  48. BACHMANN MF, Mohsen MO, Speiser DE
    The Future of SARS-CoV-2 Vaccination.
    N Engl J Med. 2022;386:899.
    PubMed    


  49. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Using Our Covid-19 Experience to Develop Vaccines More Quickly.
    N Engl J Med. 2022;386:e29.
    PubMed    


  50. ZHAO X, Li D, Ruan W, Chen Z, et al
    Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant.
    N Engl J Med. 2022;386:894-896.
    PubMed    


  51. WALTER EB, Talaat KR, Gurtman A
    More on BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. Reply.
    N Engl J Med. 2022;386.
    PubMed    


  52. LEIBOWITZ R, Schurr E, Hirsch O
    More on BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
    N Engl J Med. 2022;386.
    PubMed    


  53. TAYTARD J, Prevost B, Corvol H
    More on BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
    N Engl J Med. 2022;386.
    PubMed    


  54. ANDREWS N, Stowe J, Kirsebom F, Toffa S, et al
    Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.
    N Engl J Med. 2022 Mar 2. doi: 10.1056/NEJMoa2119451.
    PubMed     Abstract available


  55. SAVILLE M, Cramer JP, Downham M, Hacker A, et al
    Delivering Pandemic Vaccines in 100 Days - What Will It Take?
    N Engl J Med. 2022 Mar 2. doi: 10.1056/NEJMp2202669.
    PubMed    


    February 2022
  56. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Understanding the Omicron Variant of SARS-CoV-2.
    N Engl J Med. 2022;386:e27.
    PubMed    


  57. HUNTER DJ, Abdool Karim SS, Baden LR, Farrar JJ, et al
    Addressing Vaccine Inequity - Covid-19 Vaccines as a Global Public Good.
    N Engl J Med. 2022 Feb 23. doi: 10.1056/NEJMe2202547.
    PubMed    


  58. MADHI SA, Kwatra G, Myers JE, Jassat W, et al
    Population Immunity and Covid-19 Severity with Omicron Variant in South Africa.
    N Engl J Med. 2022 Feb 23. doi: 10.1056/NEJMoa2119658.
    PubMed     Abstract available


  59. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: A New Antiviral against Covid-19.
    N Engl J Med. 2022;386:e25.
    PubMed    


  60. AHMAD A, Eze K, Noulin N, Horvathova V, et al
    EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge.
    N Engl J Med. 2022;386:655-666.
    PubMed     Abstract available


  61. HAMMERMAN A, Sergienko R, Friger M, Beckenstein T, et al
    Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19.
    N Engl J Med. 2022 Feb 16. doi: 10.1056/NEJMoa2119497.
    PubMed     Abstract available


  62. HALL V, Foulkes S, Insalata F, Kirwan P, et al
    Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection.
    N Engl J Med. 2022 Feb 16. doi: 10.1056/NEJMoa2118691.
    PubMed     Abstract available


  63. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Covid-19 as an Endemic Disease.
    N Engl J Med. 2022;386:e21.
    PubMed    


  64. ARBEL R, Sergienko R, Hammerman A
    BNT162b2 Vaccine Booster and Covid-19 Mortality. Reply.
    N Engl J Med. 2022 Feb 9. pii: 10.1056/NEJMc2120044.
    PubMed    


  65. PILZ S
    BNT162b2 Vaccine Booster and Covid-19 Mortality.
    N Engl J Med. 2022 Feb 9. pii: 10.1056/NEJMc2120044.
    PubMed    


  66. ROHBAN T
    BNT162b2 Vaccine Booster and Covid-19 Mortality.
    N Engl J Med. 2022 Feb 9. pii: 10.1056/NEJMc2120044.
    PubMed    


  67. SADOFF J, Gray G, Vandebosch A, Cardenas V, et al
    Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S.
    N Engl J Med. 2022 Feb 9. doi: 10.1056/NEJMoa2117608.
    PubMed     Abstract available


  68. MAYR FB, Talisa VB, Shaikh O, Yende S, et al
    Effectiveness of Homologous or Heterologous Covid-19 Boosters in Veterans.
    N Engl J Med. 2022 Feb 9. doi: 10.1056/NEJMc2200415.
    PubMed    



  69. Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants.
    N Engl J Med. 2022;386:500.
    PubMed    


  70. MURPHY WJ, Longo DL
    Anti-idiotype Antibodies in SARS-CoV-2 Infection and Vaccination. Reply.
    N Engl J Med. 2022 Feb 2. pii: 10.1056/NEJMc2119443.
    PubMed    


  71. HARVILLE TO, Arthur JM
    Anti-idiotype Antibodies in SARS-CoV-2 Infection and Vaccination.
    N Engl J Med. 2022 Feb 2. pii: 10.1056/NEJMc2119443.
    PubMed    


  72. DE MARIA A
    Anti-idiotype Antibodies in SARS-CoV-2 Infection and Vaccination.
    N Engl J Med. 2022 Feb 2. pii: 10.1056/NEJMc2119443.
    PubMed    


    January 2022
  73. RUBIN EJ, Baden LR, Barocas JA, Morrissey S, et al
    Audio Interview: Addressing the Omicron Variant of SARS-CoV-2.
    N Engl J Med. 2022;386:e16.
    PubMed    


  74. PAJON R, Doria-Rose NA, Shen X, Schmidt SD, et al
    SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination.
    N Engl J Med. 2022 Jan 26. doi: 10.1056/NEJMc2119912.
    PubMed    


  75. MEVORACH D, Anis E, Cedar N, Hasin T, et al
    Myocarditis after BNT162b2 Vaccination in Israeli Adolescents.
    N Engl J Med. 2022 Jan 26. doi: 10.1056/NEJMc2116999.
    PubMed    


  76. ABU-RADDAD LJ, Chemaitelly H, Bertollini R
    Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar.
    N Engl J Med. 2022 Jan 26. doi: 10.1056/NEJMc2119432.
    PubMed    


  77. ATMAR RL, Lyke KE, Deming ME, Jackson LA, et al
    Homologous and Heterologous Covid-19 Booster Vaccinations.
    N Engl J Med. 2022 Jan 26. doi: 10.1056/NEJMoa2116414.
    PubMed     Abstract available


  78. RUBIN EJ, Baden LR, Fineberg HV, Morrissey S, et al
    Audio Interview: Crushing the Covid-19 Curve.
    N Engl J Med. 2022;386:e13.
    PubMed    


  79. SABLEROLLES RSG, Rietdijk WJR, Goorhuis A, Postma DF, et al
    Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming.
    N Engl J Med. 2022 Jan 19. doi: 10.1056/NEJMoa2116747.
    PubMed     Abstract available


  80. WALTER EB, Talaat KR, Gurtman A
    BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. Reply.
    N Engl J Med. 2022;386.
    PubMed    


  81. MINTZKER Y
    BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
    N Engl J Med. 2022;386.
    PubMed    


  82. FANG SF, Liu N, Du HW
    BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
    N Engl J Med. 2022;386.
    PubMed    


  83. ABU-RADDAD LJ, Chemaitelly H, Bertollini R
    Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar.
    N Engl J Med. 2022 Jan 19. doi: 10.1056/NEJMc2117933.
    PubMed    


  84. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Covid-19 Takeaways at Podcast 100.
    N Engl J Med. 2022;386:e11.
    PubMed    


  85. ROSSLER A, Riepler L, Bante D, von Laer D, et al
    SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons.
    N Engl J Med. 2022 Jan 12. doi: 10.1056/NEJMc2119236.
    PubMed    


  86. OLSON SM, Newhams MM, Halasa NB, Price AM, et al
    Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents.
    N Engl J Med. 2022 Jan 12. doi: 10.1056/NEJMoa2117995.
    PubMed     Abstract available


  87. ANDREWS N, Tessier E, Stowe J, Gower C, et al
    Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines.
    N Engl J Med. 2022 Jan 12. doi: 10.1056/NEJMoa2115481.
    PubMed     Abstract available


  88. EDWARDS KM
    Sparing of Severe Covid-19 in Vaccinated Adolescents.
    N Engl J Med. 2022 Jan 12. doi: 10.1056/NEJMe2118471.
    PubMed    


  89. LIN DY, Gu Y, Wheeler B, Young H, et al
    Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina.
    N Engl J Med. 2022 Jan 12. doi: 10.1056/NEJMoa2117128.
    PubMed     Abstract available


  90. EYRE DW, Taylor D, Purver M, Chapman D, et al
    Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants.
    N Engl J Med. 2022 Jan 5. doi: 10.1056/NEJMoa2116597.
    PubMed     Abstract available


  91. GONEN T, Lustig Y, Regev-Yochay G
    Covid-19 Infections in Vaccinated Health Care Workers. Reply.
    N Engl J Med. 2022;386.
    PubMed    


  92. RASTMANESH R
    Covid-19 Infections in Vaccinated Health Care Workers.
    N Engl J Med. 2022;386.
    PubMed    


    December 2021
  93. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Covid-19 Vaccination and the Omicron Variant.
    N Engl J Med. 2021;385:e102.
    PubMed    


  94. RITTENBERG E
    Trust, Faith, and Covid.
    N Engl J Med. 2021;385:2504-2505.
    PubMed    


  95. SCHMIDT F, Muecksch F, Weisblum Y, Da Silva J, et al
    Plasma Neutralization of the SARS-CoV-2 Omicron Variant.
    N Engl J Med. 2021 Dec 30. doi: 10.1056/NEJMc2119641.
    PubMed    


  96. COLLIE S, Champion J, Moultrie H, Bekker LG, et al
    Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa.
    N Engl J Med. 2021 Dec 29. doi: 10.1056/NEJMc2119270.
    PubMed    


  97. NEMET I, Kliker L, Lustig Y, Zuckerman N, et al
    Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection.
    N Engl J Med. 2021 Dec 29. doi: 10.1056/NEJMc2119358.
    PubMed    


  98. MCGREW S, Taylor HA
    Adolescents, Parents, and Covid-19 Vaccination - Who Should Decide?
    N Engl J Med. 2021 Dec 29. doi: 10.1056/NEJMp2116771.
    PubMed    


  99. KISSLER SM, Fauver JR, Mack C, Tai CG, et al
    Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Persons.
    N Engl J Med. 2021;385:2489-2491.
    PubMed    


  100. FOXWORTH R, Redvers N, Moreno MA, Lopez-Carmen VA, et al
    Covid-19 Vaccination in American Indians and Alaska Natives - Lessons from Effective Community Responses.
    N Engl J Med. 2021;385:2403-2406.
    PubMed    


  101. MUHSEN K, Maimon N, Mizrahi A, Varticovschi B, et al
    Effects of BNT162b2 Covid-19 Vaccine Booster in Long-Term Care Facilities in Israel.
    N Engl J Med. 2021 Dec 22. doi: 10.1056/NEJMc2117385.
    PubMed    


  102. LACY J, Pavord S, Brown KE
    VITT and Second Doses of Covid-19 Vaccine.
    N Engl J Med. 2021 Dec 22. doi: 10.1056/NEJMc2118507.
    PubMed    


  103. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: How Much Protection Does Prior SARS-CoV-2 Infection Provide?
    N Engl J Med. 2021;385:e100.
    PubMed    


  104. MORENS DM, Taubenberger JK, Fauci AS
    Universal Coronavirus Vaccines - An Urgent Need.
    N Engl J Med. 2021 Dec 15. doi: 10.1056/NEJMp2118468.
    PubMed    


  105. HORTON LE, Abeles SR, Torriani FJ
    SARS-CoV-2 Infection in Vaccinated Health Care Workers. Reply.
    N Engl J Med. 2021 Dec 15. pii: 10.1056/NEJMc2117119.
    PubMed    


  106. LILLERI D, Marena C, Baldanti F
    SARS-CoV-2 Infection in Vaccinated Health Care Workers.
    N Engl J Med. 2021 Dec 15. pii: 10.1056/NEJMc2117119.
    PubMed    


  107. DUNKLE LM, Kotloff KL, Gay CL, Anez G, et al
    Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.
    N Engl J Med. 2021 Dec 15. doi: 10.1056/NEJMoa2116185.
    PubMed     Abstract available


  108. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Waning Immunity against SARS-CoV-2.
    N Engl J Med. 2021;385:e99.
    PubMed    


  109. ARBEL R, Hammerman A, Sergienko R, Friger M, et al
    BNT162b2 Vaccine Booster and Mortality Due to Covid-19.
    N Engl J Med. 2021 Dec 8. doi: 10.1056/NEJMoa2115624.
    PubMed     Abstract available


  110. MCGARRY BE, Barnett ML, Grabowski DC, Gandhi AD, et al
    Nursing Home Staff Vaccination and Covid-19 Outcomes.
    N Engl J Med. 2021 Dec 8. doi: 10.1056/NEJMc2115674.
    PubMed    


  111. BAR-ON YM, Goldberg Y, Mandel M, Bodenheimer O, et al
    Protection against Covid-19 by BNT162b2 Booster across Age Groups.
    N Engl J Med. 2021 Dec 8. doi: 10.1056/NEJMoa2115926.
    PubMed     Abstract available


  112. CAFORIO ALP
    Receipt of mRNA Vaccine against Covid-19 and Myocarditis.
    N Engl J Med. 2021;385:2189-2190.
    PubMed    


  113. RUBIN EJ, Baden LR, Abdool Karim SS, Morrissey S, et al
    Audio Interview: The Omicron Variant of SARS-CoV-2.
    N Engl J Med. 2021;385:e96.
    PubMed    


  114. RUBIN EJ, Longo DL
    Covid-19 mRNA Vaccines - Six of One, Half a Dozen of the Other.
    N Engl J Med. 2021 Dec 1. doi: 10.1056/NEJMe2117446.
    PubMed    


  115. ROSENBERG ES, Dorabawila V, Easton D, Bauer UE, et al
    Covid-19 Vaccine Effectiveness in New York State.
    N Engl J Med. 2021 Dec 1. doi: 10.1056/NEJMoa2116063.
    PubMed     Abstract available


  116. DICKERMAN BA, Gerlovin H, Madenci AL, Kurgansky KE, et al
    Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans.
    N Engl J Med. 2021 Dec 1. doi: 10.1056/NEJMoa2115463.
    PubMed     Abstract available


    November 2021
  117. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: What's Gone Right in Our Battle against Covid-19.
    N Engl J Med. 2021;385:e95.
    PubMed    


  118. MURPHY WJ, Longo DL
    A Possible Role for Anti-idiotype Antibodies in SARS-CoV-2 Infection and Vaccination.
    N Engl J Med. 2021 Nov 24. doi: 10.1056/NEJMcibr2113694.
    PubMed    


  119. RUBIN EJ, Baden LR, Mello MM, Morrissey S, et al
    Audio Interview: The Legal Basis for Covid-19 Restrictions and Mandates.
    N Engl J Med. 2021;385:e88.
    PubMed    


  120. RUBIN EJ, Baden LR, Grinsztejn B, Morrissey S, et al
    Audio Interview: Covid-19 in Brazil and New Evidence for Vaccinating Younger Children.
    N Engl J Med. 2021;385:e79.
    PubMed    


  121. LOPEZ BERNAL J, Gower C, Andrews N
    Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. Reply.
    N Engl J Med. 2021 Nov 10. pii: 10.1056/NEJMc2113090.
    PubMed    


  122. EMANI VR, Reddy R, Goswami S
    Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.
    N Engl J Med. 2021 Nov 10. pii: 10.1056/NEJMc2113090.
    PubMed    


  123. LINSENMEYER K, Gupta K, Charness ME
    Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.
    N Engl J Med. 2021 Nov 10. pii: 10.1056/NEJMc2113090.
    PubMed    


  124. TORGOVNICK J
    Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.
    N Engl J Med. 2021 Nov 10. pii: 10.1056/NEJMc2113090.
    PubMed    


  125. WALTER EB, Talaat KR, Sabharwal C, Gurtman A, et al
    Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
    N Engl J Med. 2021 Nov 9. doi: 10.1056/NEJMoa2116298.
    PubMed     Abstract available


  126. MONTO AS
    The Future of SARS-CoV-2 Vaccination - Lessons from Influenza.
    N Engl J Med. 2021 Nov 6. doi: 10.1056/NEJMp2113403.
    PubMed    


  127. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Do We Have the Tools to End the Covid-19 Pandemic?
    N Engl J Med. 2021;385:e78.
    PubMed    


  128. SCHONBORN L, Thiele T, Kaderali L, Greinacher A, et al
    Decline in Pathogenic Antibodies over Time in VITT.
    N Engl J Med. 2021;385:1815-1816.
    PubMed    


  129. SCULLY M
    VITT after ChAdOx1 nCoV-19 Vaccination. Reply.
    N Engl J Med. 2021 Nov 3. pii: 10.1056/NEJMc2111026.
    PubMed    


  130. GREINACHER A, Schonborn L, Thiele T
    VITT after ChAdOx1 nCoV-19 Vaccination. Reply.
    N Engl J Med. 2021 Nov 3. pii: 10.1056/NEJMc2111026.
    PubMed    


  131. WEBER C, von Hundelshausen P, Siess W
    VITT after ChAdOx1 nCoV-19 Vaccination.
    N Engl J Med. 2021 Nov 3. pii: 10.1056/NEJMc2111026.
    PubMed    


  132. SANTIN AD
    VITT after ChAdOx1 nCoV-19 Vaccination.
    N Engl J Med. 2021 Nov 3. pii: 10.1056/NEJMc2111026.
    PubMed    


  133. URIU K, Kimura I, Shirakawa K, Takaori-Kondo A, et al
    Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum.
    N Engl J Med. 2021 Nov 3. doi: 10.1056/NEJMc2114706.
    PubMed    


    October 2021
  134. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: A New Monoclonal Antibody for Covid-19 and Potential Vaccination for Children.
    N Engl J Med. 2021;385:e74.
    PubMed    


  135. ASKENASE PW
    Rare Skin Reactions after mRNA Vaccination, Similar to Jones-Mote Basophil Responses.
    N Engl J Med. 2021;385:1720-1721.
    PubMed    


  136. GOLDBERG Y, Mandel M, Bar-On YM, Bodenheimer O, et al
    Waning Immunity after the BNT162b2 Vaccine in Israel.
    N Engl J Med. 2021 Oct 27. doi: 10.1056/NEJMoa2114228.
    PubMed     Abstract available


  137. DAGAN N, Barda N, Balicer RD
    Adverse Effects after BNT162b2 Vaccine and SARS-CoV-2 Infection, According to Age and Sex.
    N Engl J Med. 2021 Oct 27. doi: 10.1056/NEJMc2115045.
    PubMed    


  138. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: A New Look at Covid-19 Vaccine Boosters.
    N Engl J Med. 2021;385:e72.
    PubMed    


  139. MAGNUS MC, Gjessing HK, Eide HN, Wilcox AJ, et al
    Covid-19 Vaccination during Pregnancy and First-Trimester Miscarriage.
    N Engl J Med. 2021 Oct 20. doi: 10.1056/NEJMc2114466.
    PubMed    


  140. CHIN ET, Leidner D, Zhang Y, Long E, et al
    Effectiveness of the mRNA-1273 Vaccine during a SARS-CoV-2 Delta Outbreak in a Prison.
    N Engl J Med. 2021 Oct 20. doi: 10.1056/NEJMc2114089.
    PubMed    


  141. SHEIKH A, Robertson C, Taylor B
    BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against Death from the Delta Variant.
    N Engl J Med. 2021 Oct 20. doi: 10.1056/NEJMc2113864.
    PubMed    


  142. REIS BY, Barda N, Leshchinsky M, Kepten E, et al
    Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents.
    N Engl J Med. 2021 Oct 20. doi: 10.1056/NEJMc2114290.
    PubMed    


  143. COLLIER AY, Yu J, McMahan K, Liu J, et al
    Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines.
    N Engl J Med. 2021 Oct 15. doi: 10.1056/NEJMc2115596.
    PubMed    


  144. NOLAN T, Fortanier AC, Leav B, Poder A, et al
    Efficacy of a Cell-Culture-Derived Quadrivalent Influenza Vaccine in Children.
    N Engl J Med. 2021;385:1485-1495.
    PubMed     Abstract available


  145. RUBIN EJ, Baden LR, Wu KJ, Morrissey S, et al
    Audio Interview: Reporting on Covid-19.
    N Engl J Med. 2021;385:e66.
    PubMed    


  146. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Are Covid-19 Vaccine Boosters Necessary?
    N Engl J Med. 2021;385:e63.
    PubMed    


  147. WITBERG G, Barda N, Hoss S, Richter I, et al
    Myocarditis after Covid-19 Vaccination in a Large Health Care Organization.
    N Engl J Med. 2021 Oct 6. doi: 10.1056/NEJMoa2110737.
    PubMed     Abstract available


  148. MEVORACH D, Anis E, Cedar N, Bromberg M, et al
    Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel.
    N Engl J Med. 2021 Oct 6. doi: 10.1056/NEJMoa2109730.
    PubMed     Abstract available


  149. CHEMAITELLY H, Tang P, Hasan MR, AlMukdad S, et al
    Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar.
    N Engl J Med. 2021 Oct 6. doi: 10.1056/NEJMoa2114114.
    PubMed     Abstract available


  150. LEVIN EG, Lustig Y, Cohen C, Fluss R, et al
    Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months.
    N Engl J Med. 2021 Oct 6. doi: 10.1056/NEJMoa2114583.
    PubMed     Abstract available


  151. THOMPSON MG, Grant L, Meece J
    Prevention of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. Reply.
    N Engl J Med. 2021 Oct 6. pii: 10.1056/NEJMc2113575.
    PubMed    


  152. ZHANG C, Yin G
    Prevention of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines.
    N Engl J Med. 2021 Oct 6. pii: 10.1056/NEJMc2113575.
    PubMed    


  153. SCHOOLEY RT
    Prevention of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines.
    N Engl J Med. 2021 Oct 6. pii: 10.1056/NEJMc2113575.
    PubMed    


  154. SANTACATTERINA M, Sanders JW, Weintraub WS
    Prevention of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines.
    N Engl J Med. 2021 Oct 6. pii: 10.1056/NEJMc2113575.
    PubMed    


    September 2021
  155. RUBIN EJ, Baden LR, Tofel R, Morrissey S, et al
    Audio Interview: Covid-19 and the Media.
    N Engl J Med. 2021;385:e59.
    PubMed    


  156. FALSEY AR, Sobieszczyk ME, Hirsch I, Sproule S, et al
    Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.
    N Engl J Med. 2021 Sep 29. doi: 10.1056/NEJMoa2105290.
    PubMed     Abstract available


  157. AMIT S, Gonen T, Regev-Yochay G
    Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. Reply.
    N Engl J Med. 2021;385.
    PubMed    


  158. JUNG J, Sung H, Kim SH
    Covid-19 Breakthrough Infections in Vaccinated Health Care Workers.
    N Engl J Med. 2021;385.
    PubMed    


  159. STUART LM
    In Gratitude for mRNA Vaccines.
    N Engl J Med. 2021 Sep 24. doi: 10.1056/NEJMcibr2111445.
    PubMed    


  160. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Vaccine Efficacy and Boosters in Covid-19.
    N Engl J Med. 2021;385:e54.
    PubMed    


  161. STOKKE JL, Szymanski LJ, Bankamp B, Pratt F, et al
    MMR Vaccine-Associated Disseminated Measles in an Immunocompromised Adolescent.
    N Engl J Med. 2021;385:1246-1248.
    PubMed    


  162. LIANG TJ, Feld JJ, Cox AL, Rice CM, et al
    Controlled Human Infection Model - Fast Track to HCV Vaccine?
    N Engl J Med. 2021;385:1235-1240.
    PubMed    


  163. EL SAHLY HM, Baden LR, Essink B, Doblecki-Lewis S, et al
    Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase.
    N Engl J Med. 2021 Sep 22. doi: 10.1056/NEJMoa2113017.
    PubMed     Abstract available


  164. PILISHVILI T, Gierke R, Fleming-Dutra KE, Farrar JL, et al
    Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel.
    N Engl J Med. 2021 Sep 22. doi: 10.1056/NEJMoa2106599.
    PubMed     Abstract available


  165. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: New Evidence on SARS-CoV-2 Vaccine Boosters.
    N Engl J Med. 2021;385:e48.
    PubMed    


  166. TEBAS P, Roberts CC, Muthumani K, Reuschel EL, et al
    Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine.
    N Engl J Med. 2021;385:e35.
    PubMed     Abstract available


  167. PATEL PD, Patel P, Liang Y, Meiring JE, et al
    Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children.
    N Engl J Med. 2021;385:1104-1115.
    PubMed     Abstract available


  168. FRENCK RW JR, Dormitzer PR, Gurtman A
    BNT162b2 Covid-19 Vaccine in Adolescents. Reply.
    N Engl J Med. 2021;385.
    PubMed    


  169. LIN CH
    BNT162b2 Covid-19 Vaccine in Adolescents.
    N Engl J Med. 2021;385.
    PubMed    


  170. SALIH F, Schonborn L, Kohler S, Franke C, et al
    Vaccine-Induced Thrombocytopenia with Severe Headache.
    N Engl J Med. 2021 Sep 15. doi: 10.1056/NEJMc2112974.
    PubMed    


  171. JARA A, Undurraga EA, Araos R
    Effectiveness of an Inactivated SARS-CoV-2 Vaccine. Reply.
    N Engl J Med. 2021;385.
    PubMed    


  172. ONISHI FJ, Goto JM
    Effectiveness of an Inactivated SARS-CoV-2 Vaccine.
    N Engl J Med. 2021;385.
    PubMed    


  173. CHI H, Chiu NC, Lin CY
    Effectiveness of an Inactivated SARS-CoV-2 Vaccine.
    N Engl J Med. 2021;385.
    PubMed    


  174. OKHOTIN A
    Effectiveness of an Inactivated SARS-CoV-2 Vaccine.
    N Engl J Med. 2021;385.
    PubMed    


  175. THOMAS SJ, Moreira ED Jr, Kitchin N, Absalon J, et al
    Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months.
    N Engl J Med. 2021 Sep 15. doi: 10.1056/NEJMoa2110345.
    PubMed     Abstract available


  176. FALSEY AR, Frenck RW Jr, Walsh EE, Kitchin N, et al
    SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3.
    N Engl J Med. 2021 Sep 15. doi: 10.1056/NEJMc2113468.
    PubMed    


  177. BAR-ON YM, Goldberg Y, Mandel M, Bodenheimer O, et al
    Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel.
    N Engl J Med. 2021 Sep 15. doi: 10.1056/NEJMoa2114255.
    PubMed     Abstract available


  178. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Protecting against Severe Disease and Transmission.
    N Engl J Med. 2021;385:e44.
    PubMed    


  179. SHAH ASV, Gribben C, Bishop J, Hanlon P, et al
    Effect of Vaccination on Transmission of SARS-CoV-2.
    N Engl J Med. 2021 Sep 8. doi: 10.1056/NEJMc2106757.
    PubMed    


  180. MEANEY-DELMAN DM, Ellington SR, Shimabukuro TT
    On Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons. Reply.
    N Engl J Med. 2021 Sep 8. pii: 10.1056/NEJMc2113516.
    PubMed    


  181. SUN H
    On Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons.
    N Engl J Med. 2021 Sep 8. pii: 10.1056/NEJMc2113516.
    PubMed    


  182. ZAUCHE LH, Wallace B, Smoots AN, Olson CK, et al
    Receipt of mRNA Covid-19 Vaccines and Risk of Spontaneous Abortion.
    N Engl J Med. 2021 Sep 8. doi: 10.1056/NEJMc2113891.
    PubMed    


  183. DEAN NE, Hogan JW, Schnitzer ME
    Covid-19 Vaccine Effectiveness and the Test-Negative Design.
    N Engl J Med. 2021 Sep 8. doi: 10.1056/NEJMe2113151.
    PubMed    


  184. THOMPSON MG, Stenehjem E, Grannis S, Ball SW, et al
    Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings.
    N Engl J Med. 2021 Sep 8. doi: 10.1056/NEJMoa2110362.
    PubMed     Abstract available



  185. mRNA Covid-19 Vaccines in Pregnant Women.
    N Engl J Med. 2021 Sep 8. doi: 10.1056/NEJMx210017.
    PubMed    



  186. Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons.
    N Engl J Med. 2021 Sep 8. doi: 10.1056/NEJMx210016.
    PubMed    


  187. WILDER-SMITH A, Mulholland K
    Effectiveness of an Inactivated SARS-CoV-2 Vaccine.
    N Engl J Med. 2021;385:946-948.
    PubMed    


  188. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: A New Round of Rising Covid-19 Numbers.
    N Engl J Med. 2021;385:e41.
    PubMed    


  189. KEEHNER J, Horton LE, Binkin NJ, Laurent LC, et al
    Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce.
    N Engl J Med. 2021 Sep 1. doi: 10.1056/NEJMc2112981.
    PubMed    


    August 2021
  190. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Assessing Vaccine Safety.
    N Engl J Med. 2021;385:e37.
    PubMed    


  191. UZUN G, Althaus K, Bakchoul T
    No Correlation between Anti-PF4 and Anti-SARS-CoV-2 Antibodies after ChAdOx1 nCoV-19 Vaccination.
    N Engl J Med. 2021 Aug 25. doi: 10.1056/NEJMc2111305.
    PubMed    


  192. BARDA N, Dagan N, Ben-Shlomo Y, Kepten E, et al
    Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.
    N Engl J Med. 2021 Aug 25. doi: 10.1056/NEJMoa2110475.
    PubMed     Abstract available


  193. CHANDRAMOHAN D, Zongo I, Sagara I, Cairns M, et al
    Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention.
    N Engl J Med. 2021 Aug 25. doi: 10.1056/NEJMoa2026330.
    PubMed     Abstract available


  194. LEE GM
    The Importance of Context in Covid-19 Vaccine Safety.
    N Engl J Med. 2021 Aug 25. doi: 10.1056/NEJMe2112543.
    PubMed    


  195. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Aspects of Covid-19 Immunity.
    N Engl J Med. 2021;385:e31.
    PubMed    


  196. VERMA AK, Lavine KJ, Lin CY
    Myocarditis after Covid-19 mRNA Vaccination.
    N Engl J Med. 2021 Aug 18. doi: 10.1056/NEJMc2109975.
    PubMed    


  197. LANGE B, Gerigk M, Tenenbaum T
    Breakthrough Infections in BNT162b2-Vaccinated Health Care Workers.
    N Engl J Med. 2021 Aug 18. doi: 10.1056/NEJMc2108076.
    PubMed    


  198. TAN CW, Chia WN, Young BE, Zhu F, et al
    Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors.
    N Engl J Med. 2021 Aug 18. doi: 10.1056/NEJMoa2108453.
    PubMed     Abstract available


  199. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Monoclonal Antibodies and Booster Shots.
    N Engl J Med. 2021;385:e29.
    PubMed    


  200. HALL VG, Ferreira VH, Ku T, Ierullo M, et al
    Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients.
    N Engl J Med. 2021 Aug 11. doi: 10.1056/NEJMc2111462.
    PubMed    


  201. ALI K, Berman G, Zhou H, Deng W, et al
    Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents.
    N Engl J Med. 2021 Aug 11. doi: 10.1056/NEJMoa2109522.
    PubMed     Abstract available


  202. PAVORD S, Scully M, Hunt BJ, Lester W, et al
    Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis.
    N Engl J Med. 2021 Aug 11. doi: 10.1056/NEJMoa2109908.
    PubMed     Abstract available


  203. WILLIAMS WW, Ingelfinger JR
    Third Time's a Charm - Covid-19 Vaccine Hope for Solid-Organ Transplant Recipients.
    N Engl J Med. 2021 Aug 11. doi: 10.1056/NEJMe2112866.
    PubMed    


  204. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Looking Back and Looking Forward - Part 2.
    N Engl J Med. 2021;385:e25.
    PubMed    


    July 2021
  205. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Looking Back and Looking Forward - Part 1.
    N Engl J Med. 2021;385:e24.
    PubMed    


  206. BERGWERK M, Gonen T, Lustig Y, Amit S, et al
    Covid-19 Breakthrough Infections in Vaccinated Health Care Workers.
    N Engl J Med. 2021 Jul 28. doi: 10.1056/NEJMoa2109072.
    PubMed     Abstract available


  207. RUBIN EJ, Baden LR, Armstrong KA, Morrissey S, et al
    Audio Interview: The Impact of Covid-19 on Trainees and Junior Faculty.
    N Engl J Med. 2021;385:e21.
    PubMed    


  208. LOPEZ BERNAL J, Andrews N, Gower C, Gallagher E, et al
    Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.
    N Engl J Med. 2021 Jul 21. doi: 10.1056/NEJMoa2108891.
    PubMed     Abstract available


  209. MADHI SA, Izu A, Pollard AJ
    ChAdOx1 nCoV-19 Vaccine Efficacy against the B.1.351 Variant. Reply.
    N Engl J Med. 2021;385.
    PubMed    


  210. STRUYF F, Sadoff J, Douoguih M
    ChAdOx1 nCoV-19 Vaccine Efficacy against the B.1.351 Variant.
    N Engl J Med. 2021;385.
    PubMed    


  211. EVANS SJW, Jewell NP
    Vaccine Effectiveness Studies in the Field.
    N Engl J Med. 2021 Jul 21. doi: 10.1056/NEJMe2110605.
    PubMed    


  212. RAPEPORT G, Smith E, Gilbert A, Catchpole A, et al
    SARS-CoV-2 Human Challenge Studies - Establishing the Model during an Evolving Pandemic.
    N Engl J Med. 2021 Jul 21. doi: 10.1056/NEJMp2106970.
    PubMed    


  213. MOON S, Alonso Ruiz A, Vieira M
    Averting Future Vaccine Injustice.
    N Engl J Med. 2021;385:193-196.
    PubMed    


  214. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Monoclonal Antibodies and Vaccine Boosts.
    N Engl J Med. 2021;385:e18.
    PubMed    


  215. EICHINGER S, Warkentin TE, Greinacher A
    Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. Reply.
    N Engl J Med. 2021;385:e11.
    PubMed    


  216. CHOI PY
    Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination.
    N Engl J Med. 2021;385:e11.
    PubMed    


  217. LAI KY, Au SY, Fong KM
    Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination.
    N Engl J Med. 2021;385:e11.
    PubMed    


  218. NORMARK J, Vikstrom L, Gwon YD, Persson IL, et al
    Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination.
    N Engl J Med. 2021 Jul 14. doi: 10.1056/NEJMc2110716.
    PubMed    


  219. BAROUCH DH, Stephenson KE, Sadoff J, Yu J, et al
    Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination.
    N Engl J Med. 2021 Jul 14. doi: 10.1056/NEJMc2108829.
    PubMed    


  220. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: How Well Are Covid-19 Vaccines Working?
    N Engl J Med. 2021;385:e15.
    PubMed    


  221. BRINKLEY-RUBINSTEIN L, Peterson M, Martin R, Chan P, et al
    Breakthrough SARS-CoV-2 Infections in Prison after Vaccination.
    N Engl J Med. 2021 Jul 7. doi: 10.1056/NEJMc2108479.
    PubMed    


  222. PATRIQUIN CJ, Laroche V, Selby R, Pendergrast J, et al
    Therapeutic Plasma Exchange in Vaccine-Induced Immune Thrombotic Thrombocytopenia.
    N Engl J Med. 2021 Jul 7. doi: 10.1056/NEJMc2109465.
    PubMed    


  223. JARA A, Undurraga EA, Gonzalez C, Paredes F, et al
    Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile.
    N Engl J Med. 2021 Jul 7. doi: 10.1056/NEJMoa2107715.
    PubMed     Abstract available


  224. EDARA VV, Pinsky BA, Suthar MS, Lai L, et al
    Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants.
    N Engl J Med. 2021 Jul 7. doi: 10.1056/NEJMc2107799.
    PubMed    


  225. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Another New Covid-19 Vaccine.
    N Engl J Med. 2021;385:e13.
    PubMed    


  226. ROPPER AH, Klein JP
    Cerebral Venous Thrombosis.
    N Engl J Med. 2021;385:59-64.
    PubMed    


    June 2021
  227. THOMPSON MG, Burgess JL, Naleway AL, Tyner H, et al
    Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines.
    N Engl J Med. 2021 Jun 30. doi: 10.1056/NEJMoa2107058.
    PubMed     Abstract available


  228. HEATH PT, Galiza EP, Baxter DN, Boffito M, et al
    Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine.
    N Engl J Med. 2021 Jun 30. doi: 10.1056/NEJMoa2107659.
    PubMed     Abstract available


  229. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: A New mRNA Vaccine.
    N Engl J Med. 2021;384:e109.
    PubMed    


  230. HARRIS RJ, Hall JA, Zaidi A, Andrews NJ, et al
    Effect of Vaccination on Household Transmission of SARS-CoV-2 in England.
    N Engl J Med. 2021 Jun 23. doi: 10.1056/NEJMc2107717.
    PubMed    


  231. KAMAR N, Abravanel F, Marion O, Couat C, et al
    Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients.
    N Engl J Med. 2021 Jun 23. doi: 10.1056/NEJMc2108861.
    PubMed    


  232. KRAUSE PR, Fleming TR, Longini IM, Peto R, et al
    SARS-CoV-2 Variants and Vaccines.
    N Engl J Med. 2021 Jun 23. doi: 10.1056/NEJMsr2105280.
    PubMed     Abstract available


  233. KOENIG PA, Schmidt FI
    Spike D614G - A Candidate Vaccine Antigen Against Covid-19.
    N Engl J Med. 2021;384:2349-2351.
    PubMed    


  234. RILEY LE
    mRNA Covid-19 Vaccines in Pregnant Women.
    N Engl J Med. 2021;384:2342-2343.
    PubMed    



  235. SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia.
    N Engl J Med. 2021;384:e92.
    PubMed    


  236. RUBIN EJ, Baden LR, Longo DL, Morrissey S, et al
    Audio Interview: Treating Complications of Covid Vaccination.
    N Engl J Med. 2021;384:e107.
    PubMed    


  237. BOURGUIGNON A, Arnold DM, Warkentin TE, Smith JW, et al
    Adjunct Immune Globulin for Vaccine-Induced Thrombotic Thrombocytopenia.
    N Engl J Med. 2021 Jun 9. doi: 10.1056/NEJMoa2107051.
    PubMed     Abstract available


  238. VANDEBOSCH A, Sadoff J, Douoguih M
    Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. Reply.
    N Engl J Med. 2021 Jun 9. pii: 10.1056/NEJMc2107809.
    PubMed    


  239. HEININGER U
    Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.
    N Engl J Med. 2021 Jun 9. pii: 10.1056/NEJMc2107809.
    PubMed    


  240. SAMARAKOON U, Alvarez-Arango S, Blumenthal KG
    Delayed Large Local Reactions to mRNA Covid-19 Vaccines in Blacks, Indigenous Persons, and People of Color.
    N Engl J Med. 2021 Jun 9. doi: 10.1056/NEJMc2108620.
    PubMed    


  241. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Vaccinating Children.
    N Engl J Med. 2021;384:e103.
    PubMed    


  242. TAPIA MD, Sow SO, Naficy A, Diallo F, et al
    Meningococcal Serogroup ACWYX Conjugate Vaccine in Malian Toddlers.
    N Engl J Med. 2021;384:2115-2123.
    PubMed     Abstract available


  243. NEWMAN AM
    Institutional Problems, Individual Solutions - The Burden on Black Physicians.
    N Engl J Med. 2021;384:2076-2078.
    PubMed    


  244. BLACHERE NE, Hacisuleyman E, Darnell RB
    Vaccine Breakthrough Infections with SARS-CoV-2 Variants. Reply.
    N Engl J Med. 2021 Jun 2. pii: 10.1056/NEJMc2107808.
    PubMed    


  245. RANA K, Mohindra R, Pinnaka L
    Vaccine Breakthrough Infections with SARS-CoV-2 Variants.
    N Engl J Med. 2021 Jun 2. pii: 10.1056/NEJMc2107808.
    PubMed    


  246. NIXON DF, Ndhlovu LC
    Vaccine Breakthrough Infections with SARS-CoV-2 Variants.
    N Engl J Med. 2021 Jun 2. pii: 10.1056/NEJMc2107808.
    PubMed    


  247. TAKUVA S, Takalani A, Garrett N, Goga A, et al
    Thromboembolic Events in the South African Ad26.COV2.S Vaccine Study.
    N Engl J Med. 2021 Jun 2. doi: 10.1056/NEJMc2107920.
    PubMed    


    May 2021
  248. FRENCK RW JR, Klein NP, Kitchin N, Gurtman A, et al
    Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.
    N Engl J Med. 2021 May 27. doi: 10.1056/NEJMoa2107456.
    PubMed     Abstract available


  249. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Protecting the Immunosuppressed against Covid-19.
    N Engl J Med. 2021;384:e88.
    PubMed    


  250. VOLPP KG, Cannuscio CC
    Incentives for Immunity - Strategies for Increasing Covid-19 Vaccine Uptake.
    N Engl J Med. 2021 May 26. doi: 10.1056/NEJMp2107719.
    PubMed    


  251. RUBIN EJ, Baden LR, Drazen JM, Taichman DB, et al
    Audio Interview: Vaccination in Nursing Homes and New Pulmonary/Critical Care Research.
    N Engl J Med. 2021;384:e89.
    PubMed    


  252. VAYNE C, Rollin J, Gruel Y, Pouplard C, et al
    PF4 Immunoassays in Vaccine-Induced Thrombotic Thrombocytopenia.
    N Engl J Med. 2021 May 19. doi: 10.1056/NEJMc2106383.
    PubMed    


  253. WHITE EM, Yang X, Blackman C, Feifer RA, et al
    Incident SARS-CoV-2 Infection among mRNA-Vaccinated and Unvaccinated Nursing Home Residents.
    N Engl J Med. 2021 May 19. doi: 10.1056/NEJMc2104849.
    PubMed    


  254. RUBIN EJ, Baden LR, Gray GE, Morrissey S, et al
    Audio Interview: Vaccination and Variants in the U.S. and South Africa.
    N Engl J Med. 2021;384:e85.
    PubMed    


  255. KEEHNER J, Abeles SR, Torriani FJ
    More on SARS-CoV-2 Infection after Vaccination in Health Care Workers. Reply.
    N Engl J Med. 2021 May 12. pii: 10.1056/NEJMc2106004.
    PubMed    


  256. TOSONI A, Mirijello A, Addolorato G
    More on SARS-CoV-2 Infection after Vaccination in Health Care Workers.
    N Engl J Med. 2021 May 12. pii: 10.1056/NEJMc2106004.
    PubMed    


  257. CHIN ET, Leidner D, Ryckman T, Liu YE, et al
    Covid-19 Vaccine Acceptance in California State Prisons.
    N Engl J Med. 2021 May 12. doi: 10.1056/NEJMc2105282.
    PubMed    


  258. LIU Y, Liu J, Xia H, Zhang X, et al
    BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants.
    N Engl J Med. 2021 May 12. doi: 10.1056/NEJMc2106083.
    PubMed    


  259. RUBIN EJ, Baden LR, Udwadia ZF, Morrissey S, et al
    Audio Interview: India's Covid-19 Crisis.
    N Engl J Med. 2021;384:e84.
    PubMed    


  260. RATZAN S, Schneider EC, Hatch H, Cacchione J, et al
    Missing the Point - How Primary Care Can Overcome Covid-19 Vaccine "Hesitancy".
    N Engl J Med. 2021 May 5. doi: 10.1056/NEJMp2106137.
    PubMed    


  261. SHINDE V, Bhikha S, Hoosain Z, Archary M, et al
    Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.
    N Engl J Med. 2021 May 5. doi: 10.1056/NEJMoa2103055.
    PubMed     Abstract available


  262. ABU-RADDAD LJ, Chemaitelly H, Butt AA
    Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants.
    N Engl J Med. 2021 May 5. doi: 10.1056/NEJMc2104974.
    PubMed    


  263. NEUZIL KM
    Interplay between Emerging SARS-CoV-2 Variants and Pandemic Control.
    N Engl J Med. 2021 May 5. doi: 10.1056/NEJMe2103931.
    PubMed    


    April 2021
  264. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Advice for Clinicians on Covid-19 Vaccines and Social Restrictions.
    N Engl J Med. 2021;384:e77.
    PubMed    


  265. GOLDFARB JL, Kreps S, Brownstein JS, Kriner DL, et al
    Beyond the First Dose - Covid-19 Vaccine Follow-through and Continued Protective Measures.
    N Engl J Med. 2021 Apr 28. doi: 10.1056/NEJMp2104527.
    PubMed    


  266. RUBIN EJ, Baden LR, Walensky RP, Morrissey S, et al
    Audio Interview: Covid-19 Vaccines and Pregnancy - A Conversation with CDC Director Rochelle Walensky.
    N Engl J Med. 2021;384:e73.
    PubMed    


  267. BLUMENTHAL KG, Saff RR, Freeman EE
    Delayed Large Local Reactions to mRNA Vaccines. Reply.
    N Engl J Med. 2021 Apr 21. pii: 10.1056/NEJMc2104751.
    PubMed    


  268. BAECK M, Marot L, Belkhir L
    Delayed Large Local Reactions to mRNA Vaccines.
    N Engl J Med. 2021 Apr 21. pii: 10.1056/NEJMc2104751.
    PubMed    


  269. BARDA N, Dagan N, Balicer RD
    BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. Reply.
    N Engl J Med. 2021;384.
    PubMed    


  270. ROEST S, Hoek RAS, Manintveld OC
    BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.
    N Engl J Med. 2021;384.
    PubMed    


  271. SADOFF J, Gray G, Vandebosch A, Cardenas V, et al
    Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.
    N Engl J Med. 2021 Apr 21. doi: 10.1056/NEJMoa2101544.
    PubMed     Abstract available


  272. HACISULEYMAN E, Hale C, Saito Y, Blachere NE, et al
    Vaccine Breakthrough Infections with SARS-CoV-2 Variants.
    N Engl J Med. 2021 Apr 21. doi: 10.1056/NEJMoa2105000.
    PubMed     Abstract available


  273. SHIMABUKURO TT, Kim SY, Myers TR, Moro PL, et al
    Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons.
    N Engl J Med. 2021 Apr 21. doi: 10.1056/NEJMoa2104983.
    PubMed     Abstract available


  274. SCULLY M, Singh D, Lown R, Poles A, et al
    Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination.
    N Engl J Med. 2021 Apr 16. doi: 10.1056/NEJMoa2105385.
    PubMed     Abstract available


  275. CINES DB, Bussel JB
    SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia.
    N Engl J Med. 2021 Apr 16. doi: 10.1056/NEJMe2106315.
    PubMed    


  276. SADOFF J, Davis K, Douoguih M
    Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination - Response from the Manufacturer.
    N Engl J Med. 2021 Apr 16. doi: 10.1056/NEJMc2106075.
    PubMed    


  277. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Vaccine Successes and Vaccine Adverse Events.
    N Engl J Med. 2021;384:e70.
    PubMed    


  278. ROSENBAUM L
    No Cure without Care - Soothing Science Skepticism.
    N Engl J Med. 2021;384:1462-1465.
    PubMed    


  279. LIU Y, Liu J, Xia H, Zhang X, et al
    Neutralizing Activity of BNT162b2-Elicited Serum.
    N Engl J Med. 2021;384:1466-1468.
    PubMed    


  280. MUIR KL, Kallam A, Koepsell SA, Gundabolu K, et al
    Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination.
    N Engl J Med. 2021 Apr 14. doi: 10.1056/NEJMc2105869.
    PubMed    


  281. ANICHINI G, Terrosi C, Gandolfo C, Gori Savellini G, et al
    SARS-CoV-2 Antibody Response in Persons with Past Natural Infection.
    N Engl J Med. 2021 Apr 14. doi: 10.1056/NEJMc2103825.
    PubMed    


  282. GREINACHER A, Thiele T, Warkentin TE, Weisser K, et al
    Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination.
    N Engl J Med. 2021 Apr 9. doi: 10.1056/NEJMoa2104840.
    PubMed     Abstract available


  283. SCHULTZ NH, Sorvoll IH, Michelsen AE, Munthe LA, et al
    Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination.
    N Engl J Med. 2021 Apr 9. doi: 10.1056/NEJMoa2104882.
    PubMed     Abstract available


  284. KATZ IT, Weintraub R, Bekker LG, Brandt AM, et al
    From Vaccine Nationalism to Vaccine Equity - Finding a Path Forward.
    N Engl J Med. 2021;384:1281-1283.
    PubMed    


  285. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Antibody Responses to Natural Infection and Vaccination.
    N Engl J Med. 2021;384:e65.
    PubMed    


  286. MOYO-GWETE T, Madzivhandila M, Makhado Z, Ayres F, et al
    Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351).
    N Engl J Med. 2021 Apr 7. doi: 10.1056/NEJMc2104192.
    PubMed    


  287. LUSTIG Y, Nemet I, Kliker L, Zuckerman N, et al
    Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2.
    N Engl J Med. 2021 Apr 7. doi: 10.1056/NEJMc2104036.
    PubMed    


  288. SHEN X, Tang H, Pajon R, Smith G, et al
    Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351.
    N Engl J Med. 2021 Apr 7. doi: 10.1056/NEJMc2103740.
    PubMed    


  289. DORIA-ROSE N, Suthar MS, Makowski M, O'Connell S, et al
    Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19.
    N Engl J Med. 2021 Apr 6. doi: 10.1056/NEJMc2103916.
    PubMed    


  290. WANG GL, Wang ZY, Duan LJ, Meng QC, et al
    Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization.
    N Engl J Med. 2021 Apr 6. doi: 10.1056/NEJMc2103022.
    PubMed    


  291. RUBIN EJ, Baden LR, Del Rio C, Akusobi C, et al
    Audio Interview: Delivering Covid-19 Vaccines to Minority Communities.
    N Engl J Med. 2021;384:e60.
    PubMed    


  292. MBALA-KINGEBENI P, Pratt C, Mutafali-Ruffin M, Pauthner MG, et al
    Ebola Virus Transmission Initiated by Relapse of Systemic Ebola Virus Disease.
    N Engl J Med. 2021;384:1240-1247.
    PubMed     Abstract available


    March 2021
  293. QUINN SC, Andrasik MP
    Addressing Vaccine Hesitancy in BIPOC Communities - Toward Trustworthiness, Partnership, and Reciprocity.
    N Engl J Med. 2021 Mar 31. doi: 10.1056/NEJMp2103104.
    PubMed    


  294. HALL MA, Studdert DM
    "Vaccine Passport" Certification - Policy and Ethical Considerations.
    N Engl J Med. 2021 Mar 31. doi: 10.1056/NEJMp2104289.
    PubMed    


  295. NACHEGA JB, Sam-Agudu NA, Mellors JW, Zumla A, et al
    Scaling Up Covid-19 Vaccination in Africa - Lessons from the HIV Pandemic.
    N Engl J Med. 2021 Mar 31. doi: 10.1056/NEJMp2103313.
    PubMed    


  296. DESMOND A, Offit PA
    On the Shoulders of Giants - From Jenner's Cowpox to mRNA Covid Vaccines.
    N Engl J Med. 2021;384:1081-1083.
    PubMed    


  297. FEINBERG MB
    Uhambo - Twists and Turns on the Journey to an Efficacious HIV-1 Vaccine.
    N Engl J Med. 2021;384:1157-1159.
    PubMed    


  298. GRAY GE, Bekker LG, Laher F, Malahleha M, et al
    Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults.
    N Engl J Med. 2021;384:1089-1100.
    PubMed     Abstract available


  299. RUBIN EJ, Baden LR, Brandt AM, Morrissey S, et al
    Audio Interview: What Earlier Epidemics Teach Us about Covid-19.
    N Engl J Med. 2021;384:e55.
    PubMed    


  300. ABDOOL KARIM SS, de Oliveira T
    New SARS-CoV-2 Variants - Clinical, Public Health, and Vaccine Implications.
    N Engl J Med. 2021 Mar 24. doi: 10.1056/NEJMc2100362.
    PubMed    


  301. KEEHNER J, Horton LE, Pfeffer MA, Longhurst CA, et al
    SARS-CoV-2 Infection after Vaccination in Health Care Workers in California.
    N Engl J Med. 2021 Mar 23. doi: 10.1056/NEJMc2101927.
    PubMed    


  302. BRADLEY T, Grundberg E, Selvarangan R, LeMaster C, et al
    Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine.
    N Engl J Med. 2021 Mar 23. doi: 10.1056/NEJMc2102051.
    PubMed    


  303. DANIEL W, Nivet M, Warner J, Podolsky DK, et al
    Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center.
    N Engl J Med. 2021 Mar 23. doi: 10.1056/NEJMc2102153.
    PubMed    


  304. BENENSON S, Oster Y, Cohen MJ, Nir-Paz R, et al
    BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers.
    N Engl J Med. 2021 Mar 23. doi: 10.1056/NEJMc2101951.
    PubMed    


  305. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Efficacy of Current Covid-19 Vaccines against Variant Viruses.
    N Engl J Med. 2021;384:e53.
    PubMed    


  306. WU K, Werner AP, Koch M, Choi A, et al
    Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine.
    N Engl J Med. 2021 Mar 17. doi: 10.1056/NEJMc2102179.
    PubMed    


  307. MADHI SA, Baillie V, Cutland CL, Voysey M, et al
    Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.
    N Engl J Med. 2021 Mar 16. doi: 10.1056/NEJMoa2102214.
    PubMed     Abstract available


  308. RUBIN EJ, Baden LR, Abraham J, Morrissey S, et al
    Audio Interview: The Implications of Changes in the Structural Biology of SARS-CoV-2.
    N Engl J Med. 2021;384:e48.
    PubMed    


  309. KRAMMER F, Srivastava K, Alshammary H, Amoako AA, et al
    Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine.
    N Engl J Med. 2021 Mar 10. doi: 10.1056/NEJMc2101667.
    PubMed    


  310. GORALNICK E, Kaufmann C, Gawande AA
    Mass-Vaccination Sites - An Essential Innovation to Curb the Covid-19 Pandemic.
    N Engl J Med. 2021 Mar 10. doi: 10.1056/NEJMp2102535.
    PubMed    


  311. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: A New SARS-CoV-2 Vaccine and a New Look at Treatment.
    N Engl J Med. 2021;384:e46.
    PubMed    


  312. BLUMENTHAL KG, Freeman EE, Saff RR, Robinson LB, et al
    Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2.
    N Engl J Med. 2021 Mar 3. doi: 10.1056/NEJMc2102131.
    PubMed    


  313. STEELFISHER GK, Blendon RJ, Caporello H
    An Uncertain Public - Encouraging Acceptance of Covid-19 Vaccines.
    N Engl J Med. 2021 Mar 3. doi: 10.1056/NEJMp2100351.
    PubMed    


  314. BARSKY BA, Reinhart E, Farmer P, Keshavjee S, et al
    Vaccination plus Decarceration - Stopping Covid-19 in Jails and Prisons.
    N Engl J Med. 2021 Mar 3. doi: 10.1056/NEJMp2100609.
    PubMed    


  315. KRAMER DB, Opel DJ, Parasidis E, Mello MM, et al
    Choices in a Crisis - Individual Preferences among SARS-CoV-2 Vaccines.
    N Engl J Med. 2021 Mar 3. doi: 10.1056/NEJMp2102146.
    PubMed    


    February 2021
  316. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: The Real-World Effectiveness of Covid-19 Vaccination.
    N Engl J Med. 2021;384:e40.
    PubMed    


  317. DAGAN N, Barda N, Kepten E, Miron O, et al
    BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.
    N Engl J Med. 2021 Feb 24. doi: 10.1056/NEJMoa2101765.
    PubMed     Abstract available


  318. UBEL PA
    Vaccinating Health Care Employees - Do They All Deserve Early Access?
    N Engl J Med. 2021 Feb 19. doi: 10.1056/NEJMpv2101203.
    PubMed    


  319. RUBIN EJ, Baden LR, Farrar JJ, Morrissey S, et al
    Audio Interview: Viral Variants and Covid-19.
    N Engl J Med. 2021;384:e38.
    PubMed    


  320. ABSALON J, Koury K, Gruber WC
    Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. Reply.
    N Engl J Med. 2021;384.
    PubMed    


  321. WANG X
    Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
    N Engl J Med. 2021;384.
    PubMed    


  322. VERGNES JN
    Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
    N Engl J Med. 2021;384.
    PubMed    


  323. SKOWRONSKI DM, De Serres G
    Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
    N Engl J Med. 2021;384.
    PubMed    


  324. KADIRE SR, Wachter RM, Lurie N
    Delayed Second Dose versus Standard Regimen for Covid-19 Vaccination.
    N Engl J Med. 2021 Feb 17. doi: 10.1056/NEJMclde2101987.
    PubMed    


  325. WU K, Werner AP, Koch M, Choi A, et al
    Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine - Preliminary Report.
    N Engl J Med. 2021 Feb 17. doi: 10.1056/NEJMc2102179.
    PubMed    


  326. ROSENBAUM L
    Escaping Catch-22 - Overcoming Covid Vaccine Hesitancy.
    N Engl J Med. 2021 Feb 12. doi: 10.1056/NEJMms2101220.
    PubMed    


  327. HALLEY MC, Mangurian C
    Caring for the Caregivers - Covid-19 Vaccination for Essential Members of the Health Care Team.
    N Engl J Med. 2021 Feb 12. doi: 10.1056/NEJMpv2101339.
    PubMed    


  328. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Does Vaccination Mean the End of Masking and Social Distancing?
    N Engl J Med. 2021;384:e32.
    PubMed    


  329. PAGE K, Melia MT, Veenhuis RT, Winter M, et al
    Randomized Trial of a Vaccine Regimen to Prevent Chronic HCV Infection.
    N Engl J Med. 2021;384:541-549.
    PubMed     Abstract available


  330. CASTELLS MC, Phillips EJ
    Maintaining Safety with SARS-CoV-2 Vaccines. Reply.
    N Engl J Med. 2021 Feb 10. pii: 10.1056/NEJMc2100766.
    PubMed    


  331. ROLLA G, Brussino L, Badiu I
    Maintaining Safety with SARS-CoV-2 Vaccines.
    N Engl J Med. 2021 Feb 10. pii: 10.1056/NEJMc2100766.
    PubMed    


  332. GERBERDING JL, Haynes BF
    Vaccine Innovations - Past and Future.
    N Engl J Med. 2021;384:393-396.
    PubMed    


  333. RUBIN EJ, Baden LR, Northam RS, Morrissey S, et al
    Audio Interview: Covid-19 and the States - A Conversation with Ralph Northam.
    N Engl J Med. 2021;384:e25.
    PubMed    


    January 2021
  334. RUBIN EJ, Baden LR, Fauci AS, Morrissey S, et al
    Audio Interview: A Covid-19 Conversation with Anthony Fauci.
    N Engl J Med. 2021;384:e22.
    PubMed    


  335. LEE TH, Chen AH
    Last-Mile Logistics of Covid Vaccination - The Role of Health Care Organizations.
    N Engl J Med. 2021 Jan 27. doi: 10.1056/NEJMp2100574.
    PubMed    


  336. HEATON PM
    The Covid-19 Vaccine-Development Multiverse. Reply.
    N Engl J Med. 2021;384.
    PubMed    


  337. KOJIMA N, Turner I, Klausner JD
    The Covid-19 Vaccine-Development Multiverse.
    N Engl J Med. 2021;384.
    PubMed    


  338. RUBIN EJ, Baden LR, Nottage K, O'Connell J, et al
    Audio Interview: An International Look at Covid-19.
    N Engl J Med. 2021;384:e19.
    PubMed    


  339. KLASS P, Ratner AJ
    Vaccinating Children against Covid-19 - The Lessons of Measles.
    N Engl J Med. 2021 Jan 20. doi: 10.1056/NEJMp2034765.
    PubMed    


  340. VAN TASSEL K, Shachar C, Hoffman S
    Covid-19 Vaccine Injuries - Preventing Inequities in Compensation.
    N Engl J Med. 2021 Jan 20. doi: 10.1056/NEJMp2034438.
    PubMed    


  341. HUGHES MT, Kahn J, Kachalia A
    Who Goes First? Government Leaders and Prioritization of SARS-CoV-2 Vaccines.
    N Engl J Med. 2021 Jan 20. doi: 10.1056/NEJMpv2036128.
    PubMed    


  342. BAJAJ SS, Stanford FC
    Beyond Tuskegee - Vaccine Distrust and Everyday Racism.
    N Engl J Med. 2021 Jan 20. doi: 10.1056/NEJMpv2035827.
    PubMed    


  343. RUBIN EJ, Baden LR, Abdool Karim SS, Morrissey S, et al
    Audio Interview: Covid-19 in South Africa and a New SARS-CoV-2 Variant.
    N Engl J Med. 2021;384:e14.
    PubMed    


  344. SADOFF J, Le Gars M, Shukarev G, Heerwegh D, et al
    Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.
    N Engl J Med. 2021 Jan 13. doi: 10.1056/NEJMoa2034201.
    PubMed     Abstract available


  345. RUBIN EJ, Baden LR, Lee TH, Morrissey S, et al
    Audio Interview: Planning for the SARS-CoV-2 Vaccine Rollout.
    N Engl J Med. 2021;384:e13.
    PubMed    


  346. WOOD S, Schulman K
    Beyond Politics - Promoting Covid-19 Vaccination in the United States.
    N Engl J Med. 2021 Jan 6. doi: 10.1056/NEJMms2033790.
    PubMed    


    December 2020
  347. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: A Look at Covid-19 Prevention and Care in 2020.
    N Engl J Med. 2020;383:e147.
    PubMed    


  348. BADEN LR, El Sahly HM, Essink B, Kotloff K, et al
    Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
    N Engl J Med. 2020 Dec 30. doi: 10.1056/NEJMoa2035389.
    PubMed     Abstract available


  349. HAYNES BF
    A New Vaccine to Battle Covid-19.
    N Engl J Med. 2020 Dec 30. doi: 10.1056/NEJMe2035557.
    PubMed    


  350. FOPPIANO PALACIOS C, Travassos MA
    Vaccinating Detained Migrants against SARS-CoV-2 - Preventing Another Tragedy.
    N Engl J Med. 2020 Dec 30. doi: 10.1056/NEJMpv2035416.
    PubMed    


  351. CASTELLS MC, Phillips EJ
    Maintaining Safety with SARS-CoV-2 Vaccines.
    N Engl J Med. 2020 Dec 30. doi: 10.1056/NEJMra2035343.
    PubMed    


  352. BAROCAS JA
    Business Not as Usual - Covid-19 Vaccination in Persons with Substance Use Disorders.
    N Engl J Med. 2020 Dec 30. doi: 10.1056/NEJMpv2035709.
    PubMed    


  353. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Covid-19 Vaccine Fundamentals.
    N Engl J Med. 2020;383:e146.
    PubMed    


  354. POLACK FP, Thomas SJ, Kitchin N, Absalon J, et al
    Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
    N Engl J Med. 2020 Dec 10. doi: 10.1056/NEJMoa2034577.
    PubMed     Abstract available


  355. RUBIN EJ, Longo DL
    SARS-CoV-2 Vaccination - An Ounce (Actually, Much Less) of Prevention.
    N Engl J Med. 2020 Dec 10. doi: 10.1056/NEJMe2034717.
    PubMed    


  356. RUBIN EJ, Baden LR, Barocas JA, Morrissey S, et al
    Audio Interview: SARS-CoV-2 Vaccination and Vulnerable Populations.
    N Engl J Med. 2020;383:e143.
    PubMed    


  357. WIDGE AT, Rouphael NG, Jackson LA, Anderson EJ, et al
    Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.
    N Engl J Med. 2020 Dec 3. doi: 10.1056/NEJMc2032195.
    PubMed    


  358. KRAUSE PR, Fleming TR, Longini IM, Peto R, et al
    Placebo-Controlled Trials of Covid-19 Vaccines - Why We Still Need Them.
    N Engl J Med. 2020 Dec 2. doi: 10.1056/NEJMp2033538.
    PubMed    


    November 2020
  359. RUBIN EJ, Baden LR, Haug CJ, Morrissey S, et al
    Audio Interview: Covid-19 in Europe and New Information on Vaccines.
    N Engl J Med. 2020;383:e134.
    PubMed    


  360. REDDY SN, Nair NP, Tate JE, Thiyagarajan V, et al
    Intussusception after Rotavirus Vaccine Introduction in India.
    N Engl J Med. 2020;383:1932-1940.
    PubMed     Abstract available


  361. RUBIN EJ, Baden LR, Woodcock J, Morrissey S, et al
    Audio Interview: An Update from Operation Warp Speed.
    N Engl J Med. 2020;383:e127.
    PubMed    


  362. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: What the U.S. Response to Covid-19 Looks Like Today.
    N Engl J Med. 2020;383:e123.
    PubMed    


    October 2020
  363. HALABI S, Heinrich A, Omer SB
    No-Fault Compensation for Vaccine Injury - The Other Side of Equitable Access to Covid-19 Vaccines.
    N Engl J Med. 2020 Oct 28. doi: 10.1056/NEJMp2030600.
    PubMed    


  364. STRASSLE C, Jardas E, Ochoa J, Berkman BE, et al
    Covid-19 Vaccine Trials and Incarcerated People - The Ethics of Inclusion.
    N Engl J Med. 2020 Oct 21. doi: 10.1056/NEJMp2025955.
    PubMed    


  365. KRAUSE PR, Gruber MF
    Emergency Use Authorization of Covid Vaccines - Safety and Efficacy Follow-up Considerations.
    N Engl J Med. 2020 Oct 16. doi: 10.1056/NEJMp2031373.
    PubMed    


  366. WARREN RC, Forrow L, Hodge DA Sr, Truog RD, et al
    Trustworthiness before Trust - Covid-19 Vaccine Trials and the Black Community.
    N Engl J Med. 2020 Oct 16. doi: 10.1056/NEJMp2030033.
    PubMed    


  367. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Vaccinology and Covid-19.
    N Engl J Med. 2020;383:e109.
    PubMed    


  368. WALSH EE, Frenck RW Jr, Falsey AR, Kitchin N, et al
    Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.
    N Engl J Med. 2020 Oct 14. doi: 10.1056/NEJMoa2027906.
    PubMed     Abstract available


  369. LEI J, Ploner A, Elfstrom KM, Wang J, et al
    HPV Vaccination and the Risk of Invasive Cervical Cancer.
    N Engl J Med. 2020;383:1340-1348.
    PubMed     Abstract available


    September 2020
  370. ANDERSON EJ, Rouphael NG, Widge AT, Jackson LA, et al
    Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.
    N Engl J Med. 2020 Sep 29. doi: 10.1056/NEJMoa2028436.
    PubMed     Abstract available


  371. CHRISTIE A, Neatherlin JC, Nichol ST, Beach M, et al
    Ebola Response Priorities in the Time of Covid-19.
    N Engl J Med. 2020;383:1202-1204.
    PubMed    


  372. SCHWARTZ JL
    Evaluating and Deploying Covid-19 Vaccines - The Importance of Transparency, Scientific Integrity, and Public Trust.
    N Engl J Med. 2020 Sep 23. doi: 10.1056/NEJMp2026393.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: